All In Biotech

Drug Trial Radar · NCT05201248

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma

Phase 1b/2, Open-Label Trial to Evaluate Safety and Preliminary Efficacy of Epcoritamab As Monotherapy or Combined With Standard-of-Care Therapies in Chinese Subjects With B-Cell Non-Hodgkin Lymphoma

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

49

Actual

Start

Mar 10, 2022

Primary completion

Oct 2027

Study completion Oct 2027

Sponsor

Lead sponsor
GenmabIndustry
Sponsor type
Industry
Collaborators
AbbVie
First posted
Jan 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). The purpose of this study is to assess the safety and toxicity of epcoritamab as a monotherapy and when combined with standard of care therapy \[Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or Rituximab and lenalidomide (R2)\] in adult participants in China with B-Cell Non-Hodgkin Lymphoma. Adverse events and change in disease activity will be assessed. Epcoritamab is an investigational drug being developed for the treatment of B-Cell Non-Hodgkin Lymphoma. Study doctors put the participants in groups called treatment arms. A monotherapy of epcoritamab and two different combination of epcoritamab with standard of care therapy (R-CHOP or R2) will be explored. Each treatment arm receives a different treatment combination depending on stage of the study and eligibility. Approximately 66 adult participants with B-Cell Non-Hodgkin Lymphoma will be enrolled in the study in approximately 21 sites in China. In the monotherapy arm (Cohort 1), participants will receive subcutaneous epcoritamab in 28-day cycles. In the combination arms (Cohorts 2 and 3), participants in Cohort 2 will receive subcutaneous epcoritamab with standard of care therapy (R-CHOP) in 21-day cycles followed by 28-day cycles, participants in Cohort 3 will receive subcutaneous epcoritamab with standard of care therapy (R2) in 28-day cycles. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

Conditions

  • B-Cell Non-Hodgkin Lymphoma

Interventions

  • EpcoritamabDrug

    Subcutaneous Injection (SC)

  • CyclophosphamideDrug

    IV Injection

  • RituximabDrug

    Intravenous (IV) Infusion

  • DoxorubicinDrug

    IV Infusion

  • VincristineDrug

    IV Infusion

  • PrednisoneDrug

    Oral; Tablet

  • LenalidomideDrug

    Oral; Capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort 1 Part 2 [(3L+) R/R DLBCL]: Best Overall Response (BOR)Time frame: Up to Approximately 5 Years
  2. Cohort 1 Part 1, Cohort 2, and Cohort 3: Number of Incidence of Dose-Limiting Toxicities (DLT)Time frame: Up to Approximately 5 Years

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • The Fifth Medical Center of PLA General Hospital /ID# 230520

    Beijing, Beijing Municipality, China

  • Peking University Third Hospital /ID# 228138

    Beijing, Beijing Municipality, China

  • Fujian Medical University Union Hospital /ID# 231890

    Fuzhou, Fujian, China

  • Sun Yat-Sen University Cancer Center /ID# 228033

    Guangzhou, Guangdong, China

  • Guangdong Provincial People's Hospital /ID# 228028

    Guangzhou, Guangdong, China

  • Nanfang Hospital of Southern Medical University /ID# 227916

    Guangzhou, Guangdong, China

  • Henan Cancer Hospital /ID# 228772

    Zhengzhou, Henan, China

  • Union Hospital affiliated to Tongji Medical College of Huazhong University of Sc /ID# 231221

    Wuhan, Hubei, China

  • Hunan Cancer Hospital /ID# 231859

    Changsha, Hunan, China

  • The First Affiliated Hospital of Soochow University /ID# 228024

    Suzhou, Jiangsu, China

  • The Affiliated Hospital of Xuzhou Medical College /ID# 228774

    Xuzhou, Jiangsu, China

  • The First Affiliated Hospital of Nanchang University /ID# 228771

    Nanchang, Jiangxi, China

  • Jiangxi Provincial Cancer Hospital /ID# 231944

    Nanchang, Jiangxi, China

  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 227724

    Shanghai, Shanghai Municipality, China

  • West China Hospital, Sichuan University /ID# 231434

    Chengdu, Sichuan, China

  • Tianjin Cancer Hospital /ID# 228135

    Tianjin, Tianjin Municipality, China

  • The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 228154

    Hangzhou, Zhejiang, China

  • Zhejiang Cancer hospital /ID# 228776

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.